However, these results imply that the overexpression of EZH2 and under-expression of FOXO1 are the main characteristics of CRC drug resistance and metastasis, with SFMBT1 and HMG20A identified as possible targets for therapeutic agents to increase drug resistance. The gene discussed is FOXO1; the disease is colorectal carcinoma.